New anticoagulant approved by NICE

Edoxaban (Lixiana) has been approved for use, within its marketing authorisation, as an option for treating and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

Further information
NICE technology appraisal TA354
The direct thrombin inhibitor is also indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more